Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev®) in South Korea, 2015–2019
Sign Up to like & getrecommendations! Published in 2020 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-020-00305-6
Abstract: The live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV; Imojev®) has been approved in South Korea for use in subjects aged ≥ 12 months since 2015. As part of the license agreement, a post-marketing surveillance study was… read more here.
Keywords: surveillance; south korea; attenuated japanese; live attenuated ... See more keywords